381 Article(s)Download |
PMID | Title | Pub. Year | #Total Relationships |
201 | 23682812 | Paclitaxel, carboplatin, and trastuzumab in a neo-adjuvant regimen for HER2-positive breast cancer. | 2013 Jul-Aug | 3 |
202 | 23697602 | An open-label safety study of lapatinib plus trastuzumab plus paclitaxel in first-line HER2-positive metastatic breast cancer. | 2013 Jun | 1 |
203 | 23870999 | Antitumor efficacy of piperine in the treatment of human HER2-overexpressing breast cancer cells. | 2013 Dec 1 | 1 |
204 | 24101324 | A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy. | 2013 Oct | 2 |
205 | 24155780 | Paclitaxel and Trastuzumab as Maintenance Therapy in Patients with HER2-Positive Metastatic Breast Cancer Who Underwent High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation. | 2013 | 2 |
206 | 24168763 | Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer. | 2013 | 6 |
207 | 24223926 | An integrated model of the transcriptome of HER2-positive breast cancer. | 2013 | 1 |
208 | 21359953 | Pilot neoadjuvant trial in HER2 positive breast cancer with combination of nab-paclitaxel and lapatinib. | 2012 Apr | 1 |
209 | 21380780 | Targeted therapy with trastuzumab for advanced salivary ductal carcinoma: case report and literature review. | 2012 Jun | 1 |
210 | 21920731 | Systematic analysis of in vitro chemosensitivity and mib-1 expression in molecular breast cancer subtypes. | 2012 Sep | 1 |
211 | 22094934 | Phase II trial of preoperative paclitaxel, gemcitabine, and trastuzumab combination therapy in HER2 positive stage II/III breast cancer: the Korean Cancer Study Group BR 07-01. | 2012 Apr | 2 |
212 | 22116711 | A new anticancer compound, oblongifolin C, inhibits tumor growth and promotes apoptosis in HeLa cells through Bax activation. | 2012 Sep 15 | 1 |
213 | 22679488 | Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel. | 2012 | 1 |
214 | 22687601 | Exploration of serum metabolomic profiles and outcomes in women with metastatic breast cancer: a pilot study. | 2012 Aug | 1 |
215 | 22772380 | Efficacy and safety of concurrent trastuzumab plus weekly paclitaxel-FEC as primary therapy for HER2-positive breast cancer in everyday clinical practice. | 2012 Aug | 1 |
216 | 22824824 | Genomic methylation profiling combined with gene expression microarray reveals the aberrant methylation mechanism involved in nasopharyngeal carcinoma taxol resistance. | 2012 Sep | 1 |
217 | 22851567 | Dramatic response to trastuzumab and paclitaxel in a patient with human epidermal growth factor receptor 2-positive metastatic cholangiocarcinoma. | 2012 Sep 20 | 1 |
218 | 23028798 | Overexpression of class III beta tubulin and amplified HER2 gene predict good response to paclitaxel and trastuzumab therapy. | 2012 | 1 |
219 | 23268070 | [A case of unresectable HER2-positive advanced gastric cancer successfully treated by combination therapy with trastuzumab and paclitaxel]. | 2012 Nov | 2 |
220 | 23422737 | Antitumor activity of HM781-36B, a pan-HER tyrosine kinase inhibitor, in HER2-amplified breast cancer cells. | 2012 Mar | 2 |
221 | 23960813 | The US FDAs withdrawal of the breast cancer indication for Avastin (bevacizumab). | 2012 Oct | 1 |
222 | 21086124 | In vivo activity of novel anti-ErbB2 antibody chA21 alone and with Paclitaxel or Trastuzumab in breast and ovarian cancer xenograft models. | 2011 Mar | 1 |
223 | 21350003 | A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer. | 2011 May 15 | 1 |
224 | 21712253 | Up-regulation of breast cancer resistance protein plays a role in HER2-mediated chemoresistance through PI3K/Akt and nuclear factor-kappa B signaling pathways in MCF7 breast cancer cells. | 2011 Aug | 2 |
225 | 21788566 | Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. | 2011 Sep 1 | 1 |
226 | 21868556 | Pathological complete response and prognosis in patients receiving neoadjuvant paclitaxel and trastuzumab with and without anthracyclines for stage II and III, HER2-positive operable breast cancer: a single-institute experience. | 2011 Sep | 1 |
227 | 21887460 | Trastuzumab enhances the anti-tumor effects of the histone deacetylase inhibitor sodium butyrate on a HER2-overexpressing breast cancer cell line. | 2011 Dec | 1 |
228 | 22135629 | A Case of Metastatic Extramammary Paget's Disease Responding to Trastuzumab plus Paclitaxel Combination Therapy. | 2011 Sep | 1 |
229 | 22173491 | Preparation of anti-HER2 monoclonal antibody-paclitaxel immunoconjugate and its biological evaluation. | 2011 Dec | 2 |
230 | 19826412 | Shc is required for ErbB2-induced inhibition of apoptosis but is dispensable for cell proliferation and disruption of cell polarity. | 2010 Jan 14 | 1 |
231 | 20095796 | Quality-of-life and quality-adjusted survival (Q-TWiST) in patients receiving lapatinib in combination with paclitaxel as first-line treatment for metastatic breast cancer. | 2010 Apr | 1 |
232 | 20145176 | Chromosome 17 polysomy without human epidermal growth factor receptor 2 amplification does not predict response to lapatinib plus paclitaxel compared with paclitaxel in metastatic breast cancer. | 2010 Feb 15 | 1 |
233 | 20150272 | Methotrexate, paclitaxel, and doxorubicin radiosensitize HER2-amplified human breast cancer cells to the Auger electron-emitting radiotherapeutic agent (111)In-NLS-trastuzumab. | 2010 Mar | 3 |
234 | 20198351 | Increase of the therapeutic effect by treating nasopharyngeal tumor with combination of HER-2 siRNA and paclitaxel. | 2010 Apr | 5 |
235 | 20218616 | Osthole suppresses fatty acid synthase expression in HER2-overexpressing breast cancer cells through modulating Akt/mTOR pathway. | 2010 Apr 28 | 1 |
236 | 20332474 | Successful neoadjuvant therapy with trastuzumab, paclitaxel and epirubicin for an elderly patient with inflammatory breast cancer. | 2010 Feb | 1 |
237 | 20473628 | A case of HER-2-positive advanced inflammatory breast cancer with invasive micropapillary component showing a clinically complete response to concurrent trastuzumab and paclitaxel treatment. | 2010 Dec | 2 |
238 | 20498641 | Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin. | 2010 Jul 22 | 5 |
239 | 20530274 | Phase II study to evaluate the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer. | 2010 Jul 10 | 1 |
240 | 20547325 | Enhancement of paclitaxel-induced apoptosis in HER2-overexpressing human breast cancer cells by a pertuzumab mimetic peptide, HRAP. | 2010 Aug | 4 |
241 | 20664599 | Expression of HER-2 affects patient survival and paclitaxel sensitivity in endometrial cancer. | 2010 Sep 7 | 6 |
242 | 20673976 | Higher sensitivity to patupilone versus paclitaxel chemotherapy in primary uterine serous papillary carcinoma cell lines with high versus low HER-2/neu expression in vitro. | 2010 Oct | 1 |
243 | 20705560 | Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer. | 2010 Aug 1 | 3 |
244 | 20975068 | Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab. | 2010 Dec 1 | 1 |
245 | 21029701 | [Efficacy and safety assessment of neoadjuvant paclitaxel and trastuzumab in Chinese women with Her-2 positive operable breast cancer]. | 2010 Jul | 2 |
246 | 21088439 | A single-arm phase II trial of first-line paclitaxel in combination with lapatinib in HER2-overexpressing metastatic breast cancer. | 2010 | 2 |
247 | 21139994 | Digitoxin activates EGR1 and synergizes with paclitaxel on human breast cancer cells. | 2010 Nov 18 | 2 |
248 | 21160270 | [A case of HER2 overexpressing advanced breast cancer with CTF therapy [cyclophosphamide, pirarubicin (THPADM), fluorouracil] showed long-term effectiveness after paclitaxel shock]. | 2010 Dec | 1 |
249 | 21188093 | Role of lapatinib in the first-line treatment of patients with metastatic breast cancer. | 2010 Jan 7 | 1 |
250 | 18548321 | A case of HER2-positive male breast cancer with lung metastases showing a good response to trastuzumab and paclitaxel treatment. | 2009 | 1 |